The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper LLP (US)

33 ARCH STREET, 26TH FLOOR, BOSTON MA 02110-1447, USA
Tel:
Work +1 617 406 6000
Fax:
Fax +1 617 406 6100
Web:
www.dlapiper.com

Matthew Holian

Tel:
Work 1 617 406 6009
Email:
DLA Piper LLP (US)

Work Department

Life Sciences

Position

Co-Chair; Partner

Career

Matt's practice involves the defense of pharmaceutical and other healthcare companies in a variety of cases, with an emphasis on serving as national counsel in complex, multi-jurisdictional product liability suits. Matt serves as the Co-Chair of the firm's US Life Sciences Sector. Matt provides strategic advice in managing mass torts from start to finish, beginning with litigation risk assessments before medications are approved and continuing through pretrial discovery, bellwether trials and, ultimately, resolution. Matt has played a leadership role in a number of federal multi-district litigations and related state court proceedings for some of the world's largest pharmaceutical companies. He also has played a significant role in expert discovery in those litigations, particularly relating to epidemiology and statistics.

Education

JD, Stanford University; BA, Harvard University


United States: Dispute resolution

Product liability, mass tort and class actions: pharmaceuticals and medical devices - defense

Within: Product liability, mass tort and class actions: pharmaceuticals and medical devices - defense

DLA Piper LLP (US) is headed by Raymond Williams in Philadelphia and Christopher Young in San Diego, and is one of the leading firms for high-profile product liability litigation and mass torts in the medical and pharmaceuticals sectors. Notable highlights include representing Medtronic and Covidien as co-national counsel in the hernia mesh litigation, and defending Pfizer and Wyeth Pharmaceuticals in product liability litigation, in which plaintiffs claim that long-term use of proton pump inhibitors (PPIs) cause various forms of kidney disease. In other work, the highly regarded Loren Brown in New York is acting for Pfizer alongside Boston-based Matthew Holian in an MDL involving claims that anti-coagulant medication Eliquis causes bleeding. Cara Edwards in New York is also recommended. In January 2018, the team welcomed Stephen Matthews and Amy Rubenstein from Porzio, Bromberg & Newman and Schiff Hardin LLP respectively; in February 2018, Matt Nickel and Mike Moore joined from Dentons.

[back to top]

Product liability, mass tort and class actions: toxic tort - defense

Within: Product liability, mass tort and class actions: toxic tort - defense

The product liability and mass torts practice at DLA Piper LLP (US) is headed by Christopher Campbell and specializes in chemical exposure litigation. The team is defending e-cigarettes manufacturer NJOY in a civil action alleging that vaping products require Proposition 65 warnings. Further, Matthew Holian in Boston and Baltimore-based John Wellschlager are acting as national counsel for BASF Catalyst in talc powder and asbestos litigation related to its predecessor Engelhard. The firm’s client base also includes Porsche, Northrop Grumman and AM General.

[back to top]

United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

Co-heads of DLA Piper LLP (US)'s practice, San Diego-based Lisa Haile and Matthew Holian in Boston, specialize in patentability and licensing strategies, and product liability and mass tort, respectively. Recent highlights include obtaining issuance of multiple patents for Aegis Therapeutics’ key product areas and assisting Pfizer and Bristol-Myers Squibb (BMS) with multidistrict and state court litigation concerning alleged defects of the clients’ blockbuster anticoagulant medication Eliquis. New York-based litigator Loren Brown has been acting for Medtronic and Covidien in product liability litigation related to complications allegedly caused by some of Covidien’s implantable hernia mesh products. San Diego’s Larry Nishnick and Austin’s Aaron Fountain are names to note for corporate investment and patent litigation respectively.

[back to top]


Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to